Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lobe Sciences Ltd (CSE: LOBE )

0.0200 +0.0050 (+33.33%)
Streaming Delayed Price Updated: 2:26 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,752
Open 0.0200
Bid (Size) 0.0150 (103,000)
Ask (Size) 0.0200 (153,000)
Prev. Close 0.0150
Today's Range 0.0200 - 0.0200
52wk Range 0.0100 - 0.0400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lobe Sciences Provides Company Review of 2023
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
From Lobe Sciences Ltd.
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-33.33%
-33.33%

More News

Read More
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
From Lobe Sciences Ltd.
Via Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
Via TheNewswire.com
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
From Lobe Sciences Ltd.
Via Business Wire
The Power Play by The Market Herald Releases New Interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals Discussing Their Latest News
Via ACCESSWIRE
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
Via FinancialNewsMedia
Exposures Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Lobe Sciences Announces Incorporation of Australian Subsidiary
Via Newsfile
Lobe Sciences Announces Closing of Private Placement
Via Newsfile
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
Via Newsfile
Topics Cannabis
Exposures Cannabis
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) Featured in Coverage of Planet MicroCap’s Virtual Investor Conference
Via Investor Brand Network
Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via Investor Brand Network
Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference
Via Newsfile
Lobe Sciences Provides Corporate Update to Investors and Stakeholders
Via Newsfile
Topics Cannabis Intellectual Property
Exposures COVID-19 Cannabis Intellectual Property
Lobe Sciences to Present At H.C. Wainwright 23rd Annual Global Investment Conference
Via Newsfile
Lobe Sciences Appoints Albert "Skip" Rizzo, Ph.D to Scientific Advisory Board
Via Newsfile
Lobe Sciences Appoints Gilberto Jesús Mendoza, President of the World Boxing Association, to Advisory Board
Via Newsfile
Lobe Sciences Clarifies Recent Promotional Activities at Request of OTC Markets
Via Newsfile
Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board
Via Newsfile
Lobe Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.